Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

12 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13ZblczKGh? NGjKdItFVVOR MXTJR|UxRTBwMECwNFch|ryP MVuxO|k2PjB6MB?=
K562 NHK4OGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rL[|czKGh? NYDGWVl3TE2VTx?= MnfzTWM2OD1yLkCwNUDPxE1? NHXVbW4yPzl3NkC4NC=>
M07e NWD5XY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\te204OiCq M{W0WGROW09? M37Be2lEPTB;MD6wNFEzKM7:TR?= MXSxO|k2PjB6MB?=
ALL3 NYLmdnRES3m2b4TvfIlkKEG|c3H5 MU[wMlHPxE1? MlTTO|IhcA>? M2TRPWROW09? NEf2NGtKSzVyPUCuNFAxPCEQvF2= M3HCNFE6QDh7NUSw
CML MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXONlAhdWmw M2i2cmROW09? M1y5XmlEPTB;MD6wNFEh|ryP NVOxUVR7OTl{MUmwNVY>
BA/F3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliwO|IhcA>? M3LBTmROW09? MnXaTWM2OD14LkW4PUDPxE1? M3yzUlI{ODh6NkS0
BA/F3 M{HZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvySZFyPzJiaB?= MVfEUXNQ NEDBUFBKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> NGH4fmIzOzB6OE[0OC=>
BA/F3 NFToUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3NkBp MUDEUXNQ M{TwSWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? M4rXXVI{ODh6NkS0
BA/F3 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrNbHJ4PzJiaB?= M{[1NWROW09? NHnj[ZZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJHQ{OTWLIH31eIFvfCC5aYToJGlEPTBib3[gNU44OTUQvF2= NIDlc|MzOzB6OE[0OC=>
BA/F3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmToO|IhcA>? NUPoR5ptTE2VTx?= MlzUTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? NIq4VFUzOzNyMUewNy=>
BA/F3 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPSZlRwPzJiaB?= M4PHV2ROW09? MlXITY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? NWnEcHBoOjN|MEG3NFM>
BA/F3 M3vUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTWU5Y4OiCq NWHkS5dMTE2VTx?= MnTPTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTzJ3MFWgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwOVHPxE1? NVnFWVVHOjN|MEG3NFM>
BA/F3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVW3NkBp M{DVfWROW09? NUWxSHdSUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MVmyN|MxOTdyMx?=
BA/F3 NGDTTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXLO|IhcA>? NXfZdmRqTE2VTx?= NYfOWmtnUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRUO1PXYhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxOTQQvF2= M4HpNFI{OzBzN{Cz
BA/F3 M2HQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\uO|IhcA>? M4TvSWROW09? Mof1TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCEQ2KtRWJNKGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAxNjByMUpOwG0> NVn6Rm5qOjN|MEG3NFM>
BA/F3 M{j0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHDO|IhcA>? NH\qWmJFVVOR MX3JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? MmP4NlM{ODF5MEO=
BA/F3 MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVf2coE5PzJiaB?= NFXjWndFVVOR MXPJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBVOzF3STDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDNwNt88US=> NFrSXIczOzNyMUewNy=>
BA/F3 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XBZ|czKGh? NV\rU|Y{TE2VTx?= NUTTRYtLUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOi53zszN M4Lic|I{OzBzN{Cz
T cell MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELNZ4g4OiCq NHS4Z5dFVVOR M4P4dWlvcGmkaYTzJIFvfGliQ1SzMUBidmRiYX70bUBETDJ6LXnu[JVk\WRiVDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDBwMECz{txO NHXoUWMyPzF3NEWxNi=>
WiDr MkHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT4d|A4OiCq MXzEUXNQ MXvJR|UxRTBwMEWyJO69VQ>? MWqxOVYyPTVzMh?=
PC3 NEPnZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjmXZdkPzJiaB?= MoizSG1UVw>? M{DvO2lEPTB;MD6wNFk1KM7:TR?= MnrYNVU3OTV3MUK=
MDA-MB-231 MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3NkBp MX7EUXNQ NE\TVIhKSzVyPUCuNFEzKM7:TR?= NX7SR45rOTV4MUW1NVI>
Hs578T M{PwNGN6fG:2b4jpZ{BCe3OjeR?= M3rVXFczKGh? Mo\MSG1UVw>? NXzIUXRtT0l3ME2wMlA{KM7:TR?= M2nMclI1ODF3M{K3
HMEC NETYRW5EgXSxdH;4bYMhSXO|YYm= M3j1fFczKGh? MnXUSG1UVw>? NY\HV4Z1T0l3ME2xMlgh|ryP NFXTT|MzPDBzNUOyOy=>
DU145 MV\DfZRwfG:6aXOgRZN{[Xl? MlXJO|IhcA>? NGm4R5FFVVOR NH;jc5NIUTVyPUCuNVYh|ryP M3\pWVI1ODF3M{K3
U251 MXTDfZRwfG:6aXOgRZN{[Xl? MortO|IhcA>? M37icWROW09? NVe0Rm16T0l3ME2yMlgyKM7:TR?= NWjn[ZJ5OjRyMUWzNlc>
NCI60 NUfYbVNMS3m2b4TvfIlkKEG|c3H5 MmDCO|IhcA>? NHnp[pdFVVOR MVTHTVUxRTVwNzFOwG0> MkLONlQxOTV|Mke=
MALME-3M M1XRXGN6fG:2b4jpZ{BCe3OjeR?= M3XGelczKGh? NETLdXhFVVOR MkDTS2k2OD14Lk[xJO69VQ>? NYfJfZRZOjRyMUWzNlc>
KM12 MUXDfZRwfG:6aXOgRZN{[Xl? NYnR[HFSPzJiaB?= MnzOSG1UVw>? M4r5XGdKPTB;Nz60OEDPxE1? M1TRXlI1ODF3M{K3
SW620 MX7DfZRwfG:6aXOgRZN{[Xl? M{i4UFczKGh? MnTjSG1UVw>? MkfZS2k2OD16LkSzJO69VQ>? MmLGNlQxOTV|Mke=
RXF 393NL NVu0N|Z1S3m2b4TvfIlkKEG|c3H5 NV\WT4hDPCCmYYnz MmHCSG1UVw>? Mkm2TWM2OD1yLkCyNVch|ryP MVOyN|I2OzB5NB?=
LXFA 983L NWHGbmM1S3m2b4TvfIlkKEG|c3H5 NFq3cJQ1KGSjeYO= M3rzbWROW09? NILsSItKSzVyPUCuNFU3PSEQvF2= M2DFflI{OjV|MEe0
PRXF DU145 M1\yNmN6fG:2b4jpZ{BCe3OjeR?= MknsOEBl[Xm| M1PrbGROW09? M1PGbGlEPTB;MD6wOlI{KM7:TR?= Mni3NlMzPTNyN{S=
PAXF 1657L MVfDfZRwfG:6aXOgRZN{[Xl? NXL6W|k4PCCmYYnz MVnEUXNQ M{PrfmlEPTB;MD6xNlEh|ryP NVr0fG1oOjN{NUOwO|Q>
CXF 1103L NXnmTJM4S3m2b4TvfIlkKEG|c3H5 NX\ZcZJLPCCmYYnz MnfhSG1UVw>? M1LsbGlEPTB;ND6zOkDPxE1? M3;KUlI{OjV|MEe0
GXF251L MorwR5l1d3SxeHnjJGF{e2G7 NWTBNpFxPCCmYYnz NXfOPHJsTE2VTx?= MX;JR|UxRTJwMkWg{txO NF7wZpozOzJ3M{C3OC=>
NCI-H23 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWm3NkBp MonTSG1UVw>? Mmn1TWM2OD1{LkK3JO69VQ>? MoCyNlM2OjFyMkC=
HCT116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXCco4xPzJiaB?= NWTPOYRKTE2VTx?= MV;JR|UxRTJwMzFOwG0> NFvWZogzOzV{MUCyNC=>
MCF7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH3Ro84OiCq NX7uXoRTTE2VTx?= MojxTWM2OD1{LkW3JO69VQ>? M13LflI{PTJzMEKw
NCI-H460 M{Hab2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrFZZQ4OiCq MVHEUXNQ MWnJR|UxRThwOUmg{txO MnzkNlM2OjFyMkC=
DLD1 NFfRcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4WwbVczKGh? NWnoZXA{TE2VTx?= NWTGemUxUUN3ME20MlYh|ryP MVqyN|U3Pzl4MB?=
NCI-H661 NFOyZYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fFOVczKGh? MYTEUXNQ Mmf2TWM2OD15Lkig{txO NGXxcoYzOzV4N{m2NC=>
A549 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlj2O|IhcA>? NY\xNItVTE2VTx?= M3P0TmlEPTB;OD6yJO69VQ>? M1L0NFI{PTZ5OU[w
U937 NVm4dGY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7VemgxPzJiaB?= MUTEUXNQ MVXJR|UxRTF{LkKg{txO NIXXTlQzOzV4N{m2NC=>
HEK293 M{DWU2Z2dmO2aX;uJGF{e2G7 NG\0eYMyOMLizszN M3zLcGROW09? M4XYbWlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN M17F[|IzPzdyNkGw
HUVEC MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzHS5IxNjF3wrFOwG0> NFiyfW04OiCq NYKxflNpTE2VTx?= NXm4PWNjUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO M1mxV|IzQDV|OUmz
HUVEC NVPVdZVTTnWwY4Tpc44hSXO|YYm= MYSxOeKh|ryP M1;BW|czKGh? NG\WO4FFVVOR MXrJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> NVvW[4JMOjJ6NUO5PVM>
Plasmodium falciparum MnnvSpVv[3Srb36gRZN{[Xl? NWfKS5FSOTEEoN88US=> M{P3c|E2KG2rbh?= NHHSdWVFVVOR Mlv6TY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO NXPCSHdJOjR3NUCzN|A>
PC3 M1njSmZ2dmO2aX;uJGF{e2G7 NYPvVYlDOC5zIN88US=> NWTRZYIxPSCq NYjtUoxWTE2VTx?= MmnlTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P Ml:5NVk1PjJ7N{W=
DU145 MlWwSpVv[3Srb36gRZN{[Xl? MlrINE4yKM7:TR?= NUXm[HdiPSCq NFO0PG5FVVOR MULJcohq[mm2czDoeY1idiCGVUG0OUBk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= M2mzclE6PDZ{OUe1
PC3 MYrLbY5ie2ViQYPzZZk> MlzpNE4yKM7:TR?= NFS2NJg2KGh? M2TuemROW09? MV7Jcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P MmPpNVk1PjJ7N{W=
DU145 MV7LbY5ie2ViQYPzZZk> MoDiNE4yKM7:TR?= M2P0dVUhcA>? Mly1SG1UVw>? NWK0S3piUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O NWrjdJppOTl2NkK5O|U>
PC3 MmniT4lv[XOnIFHzd4F6 NW\2ZYY6OC5zIN88US=> MoLKOUBp NUnxTnpWTE2VTx?= MlfZTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJGZCUyC\NUe2M3k2PzdibHX2[Ywh[XRiMUCwJI5O NFTHNIEyQTR4Mkm3OS=>
DU145 MnH6T4lv[XOnIFHzd4F6 MmLaNE4yKM7:TR?= MmH2OUBp Mo\iSG1UVw>? M4HNSWlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P Ml\oNVk1PjJ7N{W=
Huh7 NWi3NldISW62aY\pdoFtKEG|c3H5 NXm2Nmo1Oi53IN88US=> NVq0SHE5PCCmYYnz MX\EUXNQ M4nqV2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQhcHWvYX6gTJVpPyClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= NF2wem8yPzN4ME[3Oi=>
C6/36 M4PNZmFvfGm4aYLhcEBCe3OjeR?= MonYNk42KM7:TR?= M3[3SVQh\GG7cx?= NGj2PI9FVVOR M{D5[WlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? M176b|E4OzZyNke2
U937 NWD1cHdMTnWwY4Tpc44hSXO|YYm= M2jpUVEh|ryP NEfUem0yKGh? MX3EUXNQ MWDS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? M1\Vc|E4Pjh2MEm5
U937 M1HJZ2Z2dmO2aX;uJGF{e2G7 MVyxJO69VQ>? NGO2UoIyKGh? NGD0eJNFVVOR MVHS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> M1fYfFE4Pjh2MEm5
murine mast cell MYnGeY5kfGmxbjDBd5NigQ>? NY\XSFFTOSEQvF2= MX[yOEBp MX\EUXNQ NVW1SYhwUW6qaXLpeJMh[W62aXflck1qdmS3Y3XkJGlNPiC|ZXPy[ZRqd25iaX6gTYdGKHC{aX3l[EBud3W|ZTDtZZN1KGOnbHzzJIF1KDFidV2= NX3JdnNJOTd4OESwPVk>
BV-173 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMECwNFAxOTB7IN88US=> Ml\zV2FPT0WU
K-562 MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jJ[mlEPTB;MD6wNFAxODB{Nk[g{txO M2\Lb3NCVkeHUh?=
BL-70 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVS5[pVrUUN3ME2wMlAxODByMEiyNkDPxE1? MoLVV2FPT0WU
EM-2 M3;1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorYTWM2OD1yLkCwNFAxOTB6IN88US=> MWXTRW5ITVJ?
LAMA-84 NHzabIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;JO2RKSzVyPUCuNFAxODB|MkGg{txO MXrTRW5ITVJ?
MEG-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMECwNFA6QCEQvF2= NVrpVmQ3W0GQR1XS
EoL-1-cell M3;neGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMECwNFE{OSEQvF2= NXzlV3pqW0GQR1XS
CTV-1 NWm0[GR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMECwNFQxPCEQvF2= NWXLfJE5W0GQR1XS
TE-15 Mmr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jPcmlEPTB;MD6wNFU5QSEQvF2= MkO3V2FPT0WU
NOS-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;DeYdxUUN3ME2wMlAxPjF|IN88US=> Mnz3V2FPT0WU
D-336MG NIH6e4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVv5XXJXUUN3ME2wMlAxPjNizszN MWHTRW5ITVJ?
LB1047-RCC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnORW8xUUN3ME2wMlAxQTh7IN88US=> M2r5e3NCVkeHUh?=
LB996-RCC NGfRWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3sUFJKSzVyPUCuNFA6QTFizszN MXHTRW5ITVJ?
SW982 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfUZ3NrUUN3ME2wMlAyOTF3IN88US=> NHvVRYRUSU6JRWK=
TK10 Mn3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jjfWlEPTB;MD6wNVE4PCEQvF2= M1LDR3NCVkeHUh?=
A704 MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXLTWM2OD1yLkCxOFkyKM7:TR?= M{j6SXNCVkeHUh?=
TE-8 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkK0TWM2OD1yLkCxOVc3KM7:TR?= NHrjcVRUSU6JRWK=
DOHH-2 M2m2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMEG3NVkh|ryP MnnmV2FPT0WU
HOP-62 NYPOVHVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT6TWM2OD1yLkCxPFM1KM7:TR?= NVnZZ3o5W0GQR1XS
TE-12 M4PkUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk[4TWM2OD1yLkCxPFYyKM7:TR?= NWHQSlhLW0GQR1XS
KGN MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LaOmlEPTB;MD6wNVk1OiEQvF2= NVnnZ4V7W0GQR1XS
NCI-H1648 NXHVNIdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjhWWhGUUN3ME2wMlAzODFzIN88US=> MoTGV2FPT0WU
OS-RC-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfOVGpKSzVyPUCuNFIxOyEQvF2= M{fGTnNCVkeHUh?=
GB-1 MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXzSGxsUUN3ME2wMlAzOTV5IN88US=> MVTTRW5ITVJ?
RXF393 M4nHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrDTWM2OD1yLkCyN|U4KM7:TR?= NXzJN|A6W0GQR1XS
LC-2-ad MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLyfFlXUUN3ME2wMlAzPTh4IN88US=> NH3XbnBUSU6JRWK=
KS-1 M1fVZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMEK3N{DPxE1? NWjwNFVDW0GQR1XS
ETK-1 NUW1TVg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;EeINKSzVyPUCuNFI5OzJizszN NX[2eXltW0GQR1XS
SW954 M3T4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7YTWM2OD1yLkCyPVI4KM7:TR?= MVXTRW5ITVJ?
Becker NYjDOpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Owb2lEPTB;MD6wN|AxOyEQvF2= NUiwfm5jW0GQR1XS
MZ1-PC NYL2clE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMEOxNVkh|ryP NIf0Z5pUSU6JRWK=
ES6 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7VPYVKSzVyPUCuNFMyQTNizszN MWXTRW5ITVJ?
KURAMOCHI NFPQS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEO0PFch|ryP M3PmXnNCVkeHUh?=
CGTH-W-1 M37TSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH6TWM2OD1yLkCzOVQ5KM7:TR?= NEeyS2JUSU6JRWK=
VA-ES-BJ NEL6bGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvVXZBKUUN3ME2wMlA{QTB{IN88US=> NGjVOW1USU6JRWK=
LXF-289 M{L0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzqd3NKSzVyPUCuNFM6PTZizszN MVTTRW5ITVJ?
MPP-89 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rUW2lEPTB;MD6wOFA1QSEQvF2= NGLIVHBUSU6JRWK=
SW872 NG\HbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TESGlEPTB;MD6wOFE3OSEQvF2= MXzTRW5ITVJ?
SNB75 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMES0N|Uh|ryP M4XPdXNCVkeHUh?=
PSN1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS4UXhKSzVyPUCuNFQ1PzRizszN NYTldmxnW0GQR1XS
LB831-BLC Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PlUmlEPTB;MD6wOFYxQSEQvF2= M2e0VXNCVkeHUh?=
MFH-ino NGrnVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL0RWFOUUN3ME2wMlA1PzJ2IN88US=> MlLzV2FPT0WU
TGBC24TKB NIPkWlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\sTWM2OD1yLkC0O|YyKM7:TR?= M1HHZXNCVkeHUh?=
A388 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTBwMEWwPVUh|ryP NVv1NZd{W0GQR1XS
BB30-HNC NUPFOVJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLpXJpKSzVyPUCuNFU1OzdizszN MXHTRW5ITVJ?
GI-ME-N M2nYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDkcG9iUUN3ME2wMlA3OTF6IN88US=> NELNVIhUSU6JRWK=
TGBC1TKB NHrLW4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{f2S2lEPTB;MD6wOlE3PCEQvF2= M{fG[HNCVkeHUh?=
TE-10 NUKzT5JmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXuZ4hlUUN3ME2wMlA3OzV5IN88US=> MlLBV2FPT0WU
A498 M2TWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LRNmlEPTB;MD6wO|I5PCEQvF2= MnvIV2FPT0WU
TE-11 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfQNHhyUUN3ME2wMlA4QDV6IN88US=> NIPtOWVUSU6JRWK=
BB65-RCC MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETGTINKSzVyPUCuNFgzOjdizszN MnHrV2FPT0WU
C2BBe1 NXyxUnc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLNTWM2OD1yLkC4N|A5KM7:TR?= NUH6W28yW0GQR1XS
NCI-H747 M{GwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjodWlKSzVyPUCuNFg{PjJizszN NYTQT|E6W0GQR1XS
IST-MES1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP6ZZFKSzVyPUCuNFg2PTJizszN M3rpVHNCVkeHUh?=
KALS-1 Ml\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEm0PUDPxE1? NWXDOYtLW0GQR1XS
GCIY MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j5fGlEPTB;MD6wPVY2PiEQvF2= NGqyW5ZUSU6JRWK=
RL95-2 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnMNHFpUUN3ME2wMlExOzhizszN NU[0OJVGW0GQR1XS
TE-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDGdnpPUUN3ME2wMlExPTRizszN NHfHd3hUSU6JRWK=
NCI-H1355 M1yyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL0[IpMUUN3ME2wMlEyODJ6IN88US=> NXXHNHZpW0GQR1XS
SW962 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnNfpY3UUN3ME2wMlEyOjl{IN88US=> M2exR3NCVkeHUh?=
KLE M4HSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXUU41KSzVyPUCuNVE{OTdizszN M3jDbXNCVkeHUh?=
MC116 NYTyc4pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMUG0NUDPxE1? NFP2OnhUSU6JRWK=
NMC-G1 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnyT5JQUUN3ME2wMlEyPjB4IN88US=> Mnm5V2FPT0WU
KU812 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDWTWM2OD1yLkGxPFg{KM7:TR?= MlTiV2FPT0WU
COLO-829 M4XwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLETWM2OD1yLkGyNlE{KM7:TR?= MYnTRW5ITVJ?
NTERA-S-cl-D1 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpRXdKSzVyPUCuNVIzQDNizszN M1TiNHNCVkeHUh?=
IST-MEL1 NILFZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL1eHdYUUN3ME2wMlE{PDVizszN Ml\3V2FPT0WU
MLMA MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG4dmZKSzVyPUCuNVQxOzJizszN M37yOXNCVkeHUh?=
LS-123 NIXWOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jlV2lEPTB;MD6xOFA3PCEQvF2= NUD0SVBrW0GQR1XS
LB2518-MEL M3[5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHWTWM2OD1yLkG0NVYzKM7:TR?= MYHTRW5ITVJ?
NB69 M3HlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL4TWM2OD1yLkG0OFM3KM7:TR?= NXjrW4tpW0GQR1XS
8-MG-BA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUWxO5pFUUN3ME2wMlE2PDV6IN88US=> MV\TRW5ITVJ?
K5 M4SyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe5NZZxUUN3ME2wMlE3PDh7IN88US=> Ml6xV2FPT0WU
KINGS-1 NWGzbFNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwMU[2OlYh|ryP M4DCdHNCVkeHUh?=
SF268 NEXxU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvKTWM2OD1yLkG3OFA1KM7:TR?= MojIV2FPT0WU
PF-382 M1Pxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDtdmRSUUN3ME2wMlE4Pjd6IN88US=> NXWzfYVuW0GQR1XS
SH-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMUi0NVMh|ryP MXzTRW5ITVJ?
NALM-6 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjKTWM2OD1yLkG5Nlk2KM7:TR?= NH;hSHVUSU6JRWK=
CP66-MEL MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP6NIxKSzVyPUCuNVk2OzFizszN NF3JelJUSU6JRWK=
697 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH2RlFKSzVyPUCuNVk6QDdizszN NWfENnRQW0GQR1XS
CP67-MEL NVXSW2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH2dWQ5UUN3ME2wMlIxPDh6IN88US=> NW\4bZR4W0GQR1XS
DSH1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M360S2lEPTB;MD6yOFAxOSEQvF2= MnrFV2FPT0WU
HCE-4 M37lW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTITWM2OD1yLkK2OFM6KM7:TR?= NFuzc3lUSU6JRWK=
MZ2-MEL NV;4enNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIH1epRKSzVyPUCuNlg2OzdizszN NXjQO4ZWW0GQR1XS
BL-41 NHuxS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf3dFZKSzVyPUCuNlkyOjNizszN NIjk[otUSU6JRWK=
HUTU-80 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwM{G0NkDPxE1? NVu5OnQyW0GQR1XS
LOXIMVI NXS2e4k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmK3TWM2OD1yLkOxOVA{KM7:TR?= M4HaUXNCVkeHUh?=
no-10 NVLKOVRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nTdWlEPTB;MD6zNVk{OSEQvF2= NGDSepVUSU6JRWK=
KARPAS-422 NUPYRmtjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILHeFZKSzVyPUCuN|M6QTdizszN MlXBV2FPT0WU
SW684 NYrS[WgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjiNnJKSzVyPUCuN|Q6QCEQvF2= NHrMcWdUSU6JRWK=
SF126 NF[1cnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXCWY86UUN3ME2wMlM2PDFizszN M3vMcXNCVkeHUh?=
D-263MG MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXrR45KSzVyPUCuN|YzOjRizszN MVTTRW5ITVJ?
OVCAR-4 NHuxNYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknkTWM2OD1yLkO3OFM{KM7:TR?= M1L5SXNCVkeHUh?=
BB49-HNC MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTBwM{i1PVkh|ryP NXLOZ2hVW0GQR1XS
ONS-76 NH;mUJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P2S2lEPTB;MD60Nlk2OSEQvF2= MoTDV2FPT0WU
MZ7-mel MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjKZ5VKSzVyPUCuOFc6OTFizszN M4e0dHNCVkeHUh?=
RCC10RGB NUTBUYhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6zZmxKSzVyPUCuOFkyOSEQvF2= MonaV2FPT0WU
BOKU MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3DTWM2OD1yLkS5NVM{KM7:TR?= MVnTRW5ITVJ?
no-11 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzMZ5FKSzVyPUCuOVAzOjhizszN NWLPToJoW0GQR1XS
IST-SL2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvDV|VKSzVyPUCuOVA{ODJizszN MWLTRW5ITVJ?
RKO NUC2WmNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4S1ZmlEPTB;MD61Nlk3PiEQvF2= NUXQd3JDW0GQR1XS
HT-144 NU\QcVc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNUO2NFkh|ryP MUfTRW5ITVJ?
NCI-H446 NVH0RlVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwNkK3OkDPxE1? NGW3b4NUSU6JRWK=
QIMR-WIL MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\DTWM2OD1yLkewOlI6KM7:TR?= MnPvV2FPT0WU
MHH-PREB-1 NYq1T3I{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXqTWM2OD1yLke0OFY6KM7:TR?= M1SyR3NCVkeHUh?=
EW-16 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPHTWM2OD1yLke2NVc5KM7:TR?= M1qxXHNCVkeHUh?=
EW-24 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHjTWM2OD1yLke4NVY2KM7:TR?= NVy4PJNxW0GQR1XS
LB373-MEL-D MmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVv3XldiUUN3ME2wMlgzPTB6IN88US=> M1jvXHNCVkeHUh?=
TE-9 NVG0b|RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXrRWhDUUN3ME2wMlg4PTN{IN88US=> MWfTRW5ITVJ?
A3-KAW MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHwSlZDUUN3ME2wMlk5PDV{IN88US=> MUXTRW5ITVJ?
A101D NH7zXXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHEbVVtUUN3ME2xMlA{ODR|IN88US=> MmPnV2FPT0WU
OCUB-M NHj4[|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjlOI5KSzVyPUGuNFQ1OTJizszN Mn[5V2FPT0WU
ES4 NHXCRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLR[pVKSzVyPUGuNFUyPDVizszN MXXTRW5ITVJ?
TE-6 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfQTWM2OD1zLkKxNlI3KM7:TR?= M{KzVHNCVkeHUh?=
D-502MG NUDKd4Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWzTWM2OD1zLkKzN|c3KM7:TR?= NFHyd2RUSU6JRWK=
KNS-42 M1LZeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fDcWlEPTB;MT6yOFQyOiEQvF2= M2T2NnNCVkeHUh?=
SNU-C2B M13tR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTFwM{C1PFkh|ryP MlfiV2FPT0WU
NCI-H1838 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nTcGlEPTB;MT6zNFc{OyEQvF2= NIHjdZNUSU6JRWK=
NKM-1 NHWyWYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG4WVVSUUN3ME2xMlMxQDV7IN88US=> M3W4RXNCVkeHUh?=
GI-1 NFuwZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofUTWM2OD1zLkO2NlIh|ryP M2rGNnNCVkeHUh?=
NB5 M1OwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX22UZc1UUN3ME2xMlM6QDJ5IN88US=> NF74b4pUSU6JRWK=
CAS-1 NHeySWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwNEC5PVIh|ryP NUH6PJN6W0GQR1XS
HCE-T M17rdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\NTWM2OD1zLkW2O|E1KM7:TR?= MkHkV2FPT0WU
SBC-1 NXrhfWxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rlcGlEPTB;MT61O|k5PCEQvF2= MU\TRW5ITVJ?
JiyoyeP-2003 NGnkR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP0ZXZTUUN3ME2xMlc{PDZ4IN88US=> MknIV2FPT0WU
TE-5 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjlc3pKSzVyPUGuO|kyOzlizszN M1vCR3NCVkeHUh?=
CAN Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTFwOEKyOVIh|ryP NIPlV21USU6JRWK=
SK-UT-1 M4\w[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\3TWM2OD1{LkG2Olk{KM7:TR?= NVrmfWtJW0GQR1XS
JVM-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTJwM{[yPFQh|ryP M4\qT3NCVkeHUh?=
LB771-HNC NGf4PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwNUe1OVEh|ryP MV\TRW5ITVJ?
NCCIT NGPqeHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTJwOE[2NVYh|ryP NXHmSnJ7W0GQR1XS
NCI-H2126 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfTTWM2OD1{Lki3OVUzKM7:TR?= MYjTRW5ITVJ?
Calu-6 M1GxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTlTWM2OD1|LkC1O|QyKM7:TR?= NVnGdY0zW0GQR1XS
SK-LMS-1 NIq3ZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfRdppWUUN3ME2zMlEyQDh4IN88US=> MkTIV2FPT0WU
ARH-77 MoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHLbXdIUUN3ME2zMlQ3QTF3IN88US=> MUfTRW5ITVJ?
NB17 NUCySJh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjENpRrUUN3ME2zMlY{QDR5IN88US=> MXzTRW5ITVJ?
A253 NGnNdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnkfFl4UUN3ME2zMlc{OjR4IN88US=> NEnMNVZUSU6JRWK=
OPM-2 MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jRcWlEPTB;ND6yO|Y5PSEQvF2= NV3BN5VsW0GQR1XS
MV-4-11 MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILCeWZKSzVyPUSuN|Y1PTRizszN M2fWbnNCVkeHUh?=
SR NXzpWnN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tt[WlEPTB;ND60PVk2PCEQvF2= NGi4VVFUSU6JRWK=
KG-1 NG\XcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPvTWM2OD12Lk[wPFQ2KM7:TR?= NFPaPYJUSU6JRWK=
OCI-AML2 MkDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFq1OWVKSzVyPUWuPFYyPTRizszN MVrTRW5ITVJ?
D-247MG NFvIN5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHuTWM2OD14LkGyOVE6KM7:TR?= NFrIcY5USU6JRWK=
DJM-1 NH\YcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTZwNEi1OVgh|ryP NFTXb5FUSU6JRWK=
RPMI-6666 NGniR5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXqTWM2OD15LkK3NFY4KM7:TR?= M17W[nNCVkeHUh?=
KARPAS-45 NXn3XFJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;hd3d6UUN3ME23MlUyPjdzIN88US=> MkL3V2FPT0WU
LP-1 NFrCNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUKzZmRsUUN3ME23MlU1Pzh{IN88US=> M4\DUXNCVkeHUh?=
RS4-11 NWnlb|NMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;sSZRqUUN3ME23MlY2Pzh5IN88US=> NIPxUlVUSU6JRWK=
DU-4475 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRThwMkG2OVIh|ryP MYPTRW5ITVJ?
MONO-MAC-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRThwMkewOlYh|ryP MXnTRW5ITVJ?
NCI-SNU-16 NWS3W5ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fhVGlEPTB;OD61OlEzQCEQvF2= NXG1d2JlW0GQR1XS
SJSA-1 M3;zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;0SHBKSzVyPUiuO|I5ODVizszN MoXzV2FPT0WU
MMAC-SF MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRThwN{mzNFch|ryP MUfTRW5ITVJ?
SK-NEP-1 MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\tPIxKSzVyPUiuPFkyPTVizszN M1XBWnNCVkeHUh?=
J-RT3-T3-5 M131d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG5Rm9KSzVyPUiuPVY2OjlizszN MoHUV2FPT0WU
SKM-1 NX7tfJZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XUVWlEPTB;OT6wNVc{PCEQvF2= NESycYFUSU6JRWK=
LB2241-RCC M3i4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFq4NGNKSzVyPUmuNFIxOTJizszN MV;TRW5ITVJ?
SIG-M5 NWnZNo9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fzeGlEPTB;OT6wNlQ6OyEQvF2= M3T4fHNCVkeHUh?=
EVSA-T MnroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTlwMke3PVMh|ryP NX\pT5pzW0GQR1XS
GT3TKB M3;ONGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTaS4VyUUN3ME25MlM2PTR4IN88US=> MkizV2FPT0WU
NB6 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;iXmdnUUN3ME25MlkzOjV7IN88US=> M{nVWnNCVkeHUh?=
EHEB M4D6cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f2b2lEPTB;MUCuNFY2PiEQvF2= NGqyRlFUSU6JRWK=
HEL NFXsdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPsUHBzUUN3ME2xNE41Pzd4IN88US=> M1SzZnNCVkeHUh?=
ALL-PO NXXv[XVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTFyLke5N|gh|ryP M3zaU3NCVkeHUh?=
TGW MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jxPWlEPTB;MUGuNlgzQCEQvF2= NHrYPJhUSU6JRWK=
BC-3 M2HOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfrOGlVUUN3ME2xNk4yOTN6IN88US=> MXrTRW5ITVJ?
IA-LM M2Pu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGixeIRKSzVyPUGyMlQ1PDVizszN MneyV2FPT0WU
UACC-257 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK4R5pKSzVyPUGyMlkyQThizszN M2TSfnNCVkeHUh?=
KP-N-YS NUfMRop7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInsNppKSzVyPUGyMlkzQDNizszN NVLlOmZmW0GQR1XS
Raji NXTvbZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LEeGlEPTB;MUOuO|Q6PyEQvF2= MoG1V2FPT0WU
SF539 M3nmU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\lTWM2OD1zMz64OVU4KM7:TR?= MX\TRW5ITVJ?
DMS-153 M4XxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\4OmlEPTB;MUSuNFAzQCEQvF2= Mof1V2FPT0WU
L-540 M1jqTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;XTHFKSzVyPUG1MlA3PzJizszN MXzTRW5ITVJ?
MN-60 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[2XGdKSzVyPUG1MlE6PzlizszN NIjz[llUSU6JRWK=
RPMI-8866 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrJfndKSzVyPUG3MlQ1PTRizszN MmDJV2FPT0WU
NCI-H510A NH\BOJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\obJRKSzVyPUG5MlM6PzNizszN NHflPHpUSU6JRWK=
NB13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDRd3VKSzVyPUG5MlQ5PzdizszN M1PhenNCVkeHUh?=
HAL-01 NHGxcGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWxeZBKSzVyPUG5Mlc2PDNizszN NY\Jfo1tW0GQR1XS
NCI-H720 NEj5O4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr6TWM2OD1{MD6yO|M{KM7:TR?= NEWyOmRUSU6JRWK=
REH NXHaZXl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0XmJKSzVyPUKwMlY{PTdizszN NFPBWXRUSU6JRWK=
KNS-81-FD M{LKfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ae2lEPTB;MkOuNVQ3KM7:TR?= MVjTRW5ITVJ?
HC-1 NF[5[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7MOoZKSzVyPUK0MlU2PTFizszN MVXTRW5ITVJ?
NCI-H2141 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPTGlEPTB;MkSuO|c2PCEQvF2= Moj0V2FPT0WU
MOLT-4 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJ4Lk[3OVMh|ryP M{nX[HNCVkeHUh?=
OMC-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jxRmlEPTB;MkeuNVQzOiEQvF2= MknYV2FPT0WU
LC-1F MnzFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyzTWM2OD1{Nz6zNlQ2KM7:TR?= M4nvZ3NCVkeHUh?=
NCI-H1304 NGexNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jrN2lEPTB;MkiuNVYzQCEQvF2= M4jncXNCVkeHUh?=
BC-1 M4TKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljmTWM2OD1{OD62OVEh|ryP NVy0b25yW0GQR1XS
NCI-H64 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEiyc4pKSzVyPUK5MlYzPTNizszN Ml;5V2FPT0WU
MOLT-16 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2mzfWlEPTB;MkmuOlI6OiEQvF2= NEX1TZBUSU6JRWK=
U-87-MG MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmC2TWM2OD1|MD63OlYh|ryP NFTKOJFUSU6JRWK=
GAK Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm3TWM2OD1|MT6yOlg3KM7:TR?= NYX5eZplW0GQR1XS
ES8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoexTWM2OD1|Mj6xNlUzKM7:TR?= NIDN[I1USU6JRWK=
HCC1599 NFXvcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fVTWlEPTB;M{KuN|MzPSEQvF2= M3jyRXNCVkeHUh?=
EB-3 NH;NbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlG2TWM2OD1|ND6zNVE4KM7:TR?= NVLXfGNzW0GQR1XS
HCC1187 M2fJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXQS45[UUN3ME2zOU45ODV{IN88US=> NUizR|J2W0GQR1XS
SK-PN-DW MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLzTWM2OD1|Nj6xPVQ{KM7:TR?= M2Du[XNCVkeHUh?=
JVM-3 NUTOeI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITnZ3NKSzVyPUO3MlI{OzhizszN MoG1V2FPT0WU
HCC2157 NWq0VlUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fwZmlEPTB;M{euPVk1PiEQvF2= NX3FVFA3W0GQR1XS
A4-Fuk NVP6VHYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfWTWM2OD1|OD6xNFA6KM7:TR?= MmXXV2FPT0WU
COR-L279 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDETWM2OD12MD6yPFUyKM7:TR?= NHfIdnlUSU6JRWK=
DEL M4nHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnhfVVKSzVyPUSxMlkxQDZizszN MUjTRW5ITVJ?
NCI-H1395 NFPzfGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn4c3JKSzVyPUSyMlAyPjNizszN NEnkNZFUSU6JRWK=
MHH-NB-11 NG[zNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPMTWM2OD12Mz6wPFE5KM7:TR?= MnTQV2FPT0WU
NCI-H2107 NWHkdJpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LHNGlEPTB;NEOuOFg1PiEQvF2= M1nFWHNCVkeHUh?=
NEC8 MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR2LkOzOkDPxE1? NVXZS2hMW0GQR1XS
COLO-684 NVPD[GtKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rQ[2lEPTB;NE[uNlI2QCEQvF2= NGCyUYhUSU6JRWK=
LS-411N MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTR6LkS3OFgh|ryP NFnWRYRUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID